Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| SanDisk | SK Hynix | Moderna | |
|---|---|---|---|
| Moat rating | narrow Narrow rather than wide: the FY2025 10-K Competition section opens 'Our industry is highly competitive' and names five vertically integrated flash rivals (Kioxia, Micron, Samsung, SK Hynix, Yangtze Memory), while Item 1A concedes SanDisk's products 'are designed to be largely interchangeable with competitors' products' in a market 'often subject to declining average selling prices'. It is not 'none', because the same filing discloses a genuinely durable consumer franchise and roughly 7,900 granted patents. | narrow SK hynix held ~62% of the AI-critical HBM market in Q2 2025 (Counterpoint, via TweakTown) and was first to mass-produce HBM4, but memory remains a cyclical three-player business where Samsung and Micron are closing the HBM gap — a real but contestable edge. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip The only hard-to-replicate assets the filing actually claims are intangible: it reports 'a strong position in the Consumer end market' with 'significant consumer brands and franchises globally, with valuable patent portfolios containing approximately 7,900 granted patents and approximately 3,200 pending patent applications worldwide', and adds that non-patented IP, 'particularly some of our process technology, is an important factor in our success'. Cost-scale is the wrong label because the manufacturing scale sits in Flash Ventures, a 49.9%-owned JV co-owned with Kioxia, not in a proprietary fab base. | intangibles ip The advantage is process-and-packaging technology leadership: SK hynix achieved industry-first HBM4 mass production in September 2025 and has positioned itself as NVIDIA's key HBM partner, per its record FY2025 results. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | at parity At parity, not ahead: the 10-K Competition section positions SanDisk against vertically integrated suppliers Kioxia, Micron, Samsung, SK Hynix and Yangtze Memory, and Item 1A concedes its products are 'designed to be largely interchangeable with competitors' products'. Its explicit leadership claims are brand- and consumer-scoped ('industry leading consumer brand awareness and global retail distribution presence'), not technology- or share-scoped. | clear leader Clear leader in HBM (#1 at ~62% share, Q2 2025) and became the world's top overall memory supplier in Q2 2025; caveat: it sits #2 to Samsung in commodity DRAM by volume and Micron/Samsung are narrowing the HBM gap heading into HBM4. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | weak A price taker. The 10-K describes an industry 'often subject to declining average selling prices' and warns that competitors 'may utilize pricing strategies, including offering products at prices at or below cost, that we may be unable to competitively match'. Gross margin swung from 7.1% (FY2023) to 16.1% (FY2024) to 30.1% (FY2025) on the cycle rather than on sustained pricing, and FY2025 Consumer ASP per gigabyte still fell 7% 'due to pricing pressure'. | strong FY2025 operating margin hit a record 49% (operating profit +101% YoY) as HBM revenue more than doubled — unusually strong pricing power for a memory maker, per SK hynix's FY25 release. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | SanDisk sells largely interchangeable NAND product into a five-rival commodity market, so its defensible edge is narrow and concentrated in intangibles: the SanDisk consumer brand and retail distribution (Consumer was $2,268M of $7,355M FY2025 revenue) plus roughly 7,900 granted patents. It owns no flash fab of its own; the 10-K says substantially all of its flash memory wafers come from Flash Ventures, its 49.9% JV with Kioxia, whose fixed costs it must fund at about half regardless of the output it takes. That structure caps both the moat and the downside cushion: gross margin ran 7.1% in FY2023, 16.1% in FY2024 and 30.1% in FY2025 as the flash cycle turned. | SK hynix's durable advantage rests on an HBM process-and-packaging lead: it held roughly 62% of the HBM market in Q2 2025 (Counterpoint) as NVIDIA's key HBM partner, and delivered industry-first HBM4 mass production. That lead drove record FY2025 results with a 49% operating margin, though rivals are qualifying competing HBM parts. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Merchant NAND/SSD supplier with no wholly owned fab: substantially all flash wafers come from Flash Ventures, its 49.9% JV with Kioxia across seven Japanese fabs, with an eighth due to start in calendar 2025. | Primary supplier of HBM (high-bandwidth memory) stacked onto NVIDIA's AI accelerators; HBM represented roughly 77% of Q2 2025 revenue. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.24 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |